Equities Analysts Offer Predictions for Amphastar Pharmaceuticals, Inc.’s Q1 2024 Earnings (NASDAQ:AMPH)

Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) – Capital One Financial issued their Q1 2024 earnings per share (EPS) estimates for Amphastar Pharmaceuticals in a research report issued to clients and investors on Wednesday, April 17th. Capital One Financial analyst T. Chiang expects that the company will post earnings per share of $0.72 for the quarter. The consensus estimate for Amphastar Pharmaceuticals’ current full-year earnings is $3.42 per share. Capital One Financial also issued estimates for Amphastar Pharmaceuticals’ Q2 2024 earnings at $0.72 EPS, Q3 2024 earnings at $1.01 EPS and Q4 2024 earnings at $1.03 EPS.

Several other analysts have also commented on AMPH. JPMorgan Chase & Co. started coverage on Amphastar Pharmaceuticals in a report on Tuesday, March 5th. They issued an “overweight” rating and a $60.00 price objective on the stock. Needham & Company LLC reissued a “hold” rating on shares of Amphastar Pharmaceuticals in a report on Wednesday, April 10th. Finally, StockNews.com downgraded Amphastar Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Thursday, February 29th. Three research analysts have rated the stock with a hold rating and two have assigned a buy rating to the company’s stock. According to MarketBeat.com, the company currently has a consensus rating of “Hold” and a consensus price target of $66.00.

Amphastar Pharmaceuticals Stock Down 2.1 %

Shares of AMPH opened at $40.05 on Thursday. The company has a current ratio of 2.17, a quick ratio of 1.70 and a debt-to-equity ratio of 0.92. Amphastar Pharmaceuticals has a 12 month low of $35.62 and a 12 month high of $67.66. The stock’s 50 day moving average is $46.59 and its two-hundred day moving average is $51.23. The firm has a market cap of $1.96 billion, a P/E ratio of 15.52, a PEG ratio of 0.97 and a beta of 0.84.

Amphastar Pharmaceuticals (NASDAQ:AMPH) last issued its quarterly earnings data on Wednesday, February 28th. The company reported $0.81 EPS for the quarter, missing the consensus estimate of $0.84 by ($0.03). Amphastar Pharmaceuticals had a net margin of 21.34% and a return on equity of 26.95%. The business had revenue of $178.11 million during the quarter, compared to analyst estimates of $174.90 million.

Hedge Funds Weigh In On Amphastar Pharmaceuticals

A number of institutional investors have recently added to or reduced their stakes in AMPH. McGlone Suttner Wealth Management Inc. purchased a new position in Amphastar Pharmaceuticals during the fourth quarter worth approximately $28,000. Principal Securities Inc. purchased a new stake in Amphastar Pharmaceuticals in the fourth quarter valued at $34,000. Point72 Middle East FZE purchased a new stake in Amphastar Pharmaceuticals in the fourth quarter valued at $50,000. Ronald Blue Trust Inc. raised its position in Amphastar Pharmaceuticals by 821.5% in the third quarter. Ronald Blue Trust Inc. now owns 1,198 shares of the company’s stock valued at $55,000 after purchasing an additional 1,068 shares during the period. Finally, China Universal Asset Management Co. Ltd. raised its position in Amphastar Pharmaceuticals by 99.2% in the third quarter. China Universal Asset Management Co. Ltd. now owns 1,261 shares of the company’s stock valued at $58,000 after purchasing an additional 628 shares during the period. Hedge funds and other institutional investors own 65.09% of the company’s stock.

Insider Activity

In other news, Director Floyd F. Petersen sold 500 shares of the firm’s stock in a transaction that occurred on Thursday, February 1st. The stock was sold at an average price of $53.10, for a total value of $26,550.00. Following the transaction, the director now owns 80,333 shares in the company, valued at $4,265,682.30. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. In related news, Director Floyd F. Petersen sold 500 shares of Amphastar Pharmaceuticals stock in a transaction that occurred on Thursday, February 1st. The stock was sold at an average price of $53.10, for a total transaction of $26,550.00. Following the transaction, the director now owns 80,333 shares in the company, valued at $4,265,682.30. The sale was disclosed in a document filed with the SEC, which is accessible through this link. Also, Director Michael A. Zasloff sold 12,500 shares of Amphastar Pharmaceuticals stock in a transaction that occurred on Tuesday, March 5th. The stock was sold at an average price of $47.18, for a total value of $589,750.00. Following the transaction, the director now owns 21,326 shares in the company, valued at approximately $1,006,160.68. The disclosure for this sale can be found here. Insiders have sold a total of 14,000 shares of company stock worth $660,860 over the last quarter. 27.80% of the stock is currently owned by corporate insiders.

Amphastar Pharmaceuticals Company Profile

Amphastar Pharmaceuticals, Inc, a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a nasal spray for the treatment of severe hypoglycemia; Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Enoxaparin, to prevent and treat deep vein thrombosis; REXTOVY and Naloxone for opioid overdose; Glucagon for injection emergency kit; and Cortrosyn, for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency.